Baoji Pharmaceutical: The follow-up of the phase III clinical trial of KJ103 for desensitization treatment in kidney transplant has been completed.

Baoji Pharmaceutical Industry announced that the Phase III clinical trial of KJ103 as a desensitization therapy for highly sensitive patients awaiting kidney transplantation in China has completed all major trial follow-ups for enrolled subjects on March 20, 2026. The company stated that they will promptly submit a new drug application to the National Medical Products Administration.